Elucigene Diagnostics, Lifecodexx Partner
News Oct 27, 2016
Elucigene Diagnostics and LifeCodexx AG announced that they have partnered with the aim of providing access for UK and Irish patients to LifeCodexx’ proprietary PrenaTest® NIPT technology.
PrenaTest® was Europe’s first non-invasive prenatal test (NIPT), significantly enhancing prenatal trisomy screening sensitivity, whilst drastically reducing invasive procedure linked pregnancy loss occurrence. The test is performed within Germany in strict conformity with the highest quality standards as per the European Directive on In-vitro Diagnostic Medical Devices. Currently, every 30 minutes a pregnant woman opts for PrenaTest® being a leading NIPT across Europe and the Middle East.
Dr. Mark Street-Docherty, Commercial Manager of Elucigene Diagnostics says “We are delighted to be able to offer pregnant women across the UK access to leading NIPT technology, ensuring safe and accurate screening for the most common chromosomal trisomies. This service complements our continued support for prenatal testing accuracy, alongside our leading QST*R diagnostic prenatal range”.
“We are very pleased to add Elucigene Diagnostics to our group of partners with their long standing expertise in the field of prenatal diagnostic in the U.K but also elsewhere,” added Dr. Michael Lutz, CEO of LifeCodexx. “With this new partnership, our high quality PrenaTest® is now available in more than 40 countries throughout Europe and the Middle East.”
Stem Cells in Menstrual Blood Could Help Diagnose EndometriosisNews
The Feinstein Institute for Medical Research scientists announced an experimental, rapid and non-invasive way to diagnose endometriosis, which may lead to earlier and more effective treatments for this disorder that affects approximately 176 million women globally.READ MORE
SMi’s 5th Annual Molecular Diagnostics Conference 2018 Agenda ReleasedNews
SMi proudly presents its 5th annual conference on Molecular Diagnostics, taking place at the Holiday Inn Kensington Forum, London, UK on 9th and 10th July 2018, with a half-day post-conference workshops on 11th July 2018.READ MORE
Pap Test Fluids Used to Test for Endometrial & Ovarian CancersNews
Cervical fluid samples gathered during routine Papanicolaou (Pap) tests are the basis of a new screening test for endometrial and ovarian cancers developed by researchers at the Johns Hopkins Kimmel Cancer Center.